December 1, 2022 | Targeted Therapies in Oncology

BI 1810631 Shows Early Antitumor Activity in NSCLC

December 04, 2022

Clinical Articles

Although HER2 mutations present in many solid tumors, lung cancer is of particular interest because a significant number of mutations are found in the tyrosine kinase domain of the gene. Of those, about 90% take the form of insertions or deletions, according study findings.

Updates Results Support Repotrectinib in ROS1+ NSCLC

December 03, 2022

Clinical Articles

Updated findings from the TRIDENT-1 suggest that repotrectinib could represent a potential new treatment option for patients with ROS1- positive advanced non–small cell lung cancer, according to Byoung Chul Cho, MD, PhD.

Oncology Societies Recognize and Address Burnout During Conferences

December 02, 2022

Clinical Articles

According to John M. Burke, MD, significant attention has been paid in recent years to the problem of physician burnout and as oncologists continue to care for patients, it important to also care for themselves.